Phase I/II Study of DS-5141b: Open-label Study of DS-5141b in Patients With Duchenne Muscular Dystrophy
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 06 Oct 2017
At a glance
- Drugs DS 5141 (Primary)
- Indications Duchenne muscular dystrophy
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Daiichi Sankyo Company
- 22 Aug 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Apr 2018.
- 21 Aug 2017 Planned End Date changed from 1 Sep 2017 to 30 Apr 2018.
- 21 Aug 2017 Status changed from recruiting to active, no longer recruiting.